We’re here for one reason and one reason only – to cure cancer. Every moment is dedicated to developing treatments and every action moves us one step closer to our goal. We’ve made incredible scientific breakthroughs and our pioneering personalized CAR T-cell therapies have changed the paradigm. But we're not finished yet.
Join Kite, as we make even bigger advances in cancer therapies, and help shape where our business and medical science goes next.
We believe every employee deserves a great leader. People Leaders are the cornerstone to the employee experience at Gilead and Kite. As a people leader now or in the future, you are the key driver in evolving our culture and creating an environment where every employee feels included, developed and empowered to fulfil their aspirations.
What you'd do
Support the Safety organization in conducting literature surveillance and targeted safety information reviews.
Assist with aggregate safety data analyses and preparation of safety summaries, tables, and presentations.
Support signal detection and signal evaluation activities under the guidance of experienced safety scientists.
Assist with review and organization of safety information from clinical trials and post-marketing sources.
Support preparation and maintenance of pharmacovigilance deliverables, including DSURs, development safety summaries, safety review materials, and risk management documentation.
Conduct targeted research on emerging safety topics, mechanisms of toxicity, and relevant medical literature.
Assist with benefit-risk assessment projects and preparation of materials for safety governance forums.
Support the development of safety surveillance strategies for novel and advanced therapies.
Participate in cross-functional meetings with Clinical Development, Biostatistics, Regulatory Affairs, Medical Affairs, and other functions to understand how patient safety is integrated into drug development.
Develop presentations and concise written summaries communicating safety findings to scientific and cross-functional audiences.